Jafra to sell Zirh
This article was originally published in The Rose Sheet
Executive Summary
Exclusive men's skin-care and fragrance products from Zirh will be sold through direct seller's more than 500,000 beauty consultants under long-term development and distribution agreement, according to recent release. Deal "not only allows Zirh to substantially increase its sales through an alternative, profitable channel, but exposes our product to consumers who may not have had the opportunity to previously try them," Brian Robinson, president of Zirh Holdings, says. Jafra notes it "is implementing substantial resources around increasing [Zirh] brand presence and impact in the U.S." First line to be sold through Jafra network will comprise eight skin-care SKUs developed in collaboration with Jafra R&D; line will launch internationally in July 2009, followed by U.S. launch in August. Juan Gomez will oversee the initiative as Jafra Project Manager, according to Zirh; prior to joining Zirh, Gomez spent 10 years at Avon and participated in development of Derek Jeter's Driven and U by Ungaro
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.